| Dr Erin Mcbride Cannington, MD | |
|
105 Spanish Ct, Albany, GA 31707-1282 | |
| (229) 438-7100 | |
| Not Available |
| Full Name | Dr Erin Mcbride Cannington |
|---|---|
| Gender | Female |
| Speciality | Allergy/immunology |
| Experience | 18 Years |
| Location | 105 Spanish Ct, Albany, Georgia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629165675 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 68127 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Phoebe Putney Memorial Hospital | Albany, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allergy And Asthma Clinics Of Ga | 1052305919 | 6 |
News Archive
Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Morphine Sulfate Extended-release (ER) Tablets, 15 mg, 30 mg, 60 mg, 100 mg and 200 mg, the generic version of Purdue Pharma's MS Contin, an opioid analgesic for moderate to severe pain management.
Rui Costa, Principal Investigator of the Champalimaud Neuroscience Programme at the Instituto Gulbenkian de Ciência, and Xin Jin, of the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, describe in the latest issue of the journal Nature, that the activity of certain neurons in the brain can signal the initiation and termination of behavioural sequences we learn anew. Furthermore, they found that this brain activity is essential for learning and executing novel action sequences, many times compromised in patients suffering from disorders such as Parkinson's or Huntington's.
Sinapis Pharma is pleased to announce that it has received notice from the FDA that its Investigational New Drug application (IND) for the use of IV methamphetamine for acute stroke was approved on April 9, 2010. "We have accomplished a great deal of work for a small company on a very tight budget. We have GMP drug ready for the Phase I clinical trial and the Phase I site is prepared to begin this protocol," said Dr. Donald Picker , the company CEO.
St. Jude Medical, Inc., a global medical device company, today announced study results on the safety and efficacy of peripheral nerve stimulation (PNS) of the occipital nerve for the management of pain and disability associated with chronic migraine, a debilitating condition that affects millions worldwide.
› Verified 2 days ago
| Entity Name | Allergy & Asthma Clinics Of Ga |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093997447 PECOS PAC ID: 1052305919 Enrollment ID: O20040413000951 |
News Archive
Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Morphine Sulfate Extended-release (ER) Tablets, 15 mg, 30 mg, 60 mg, 100 mg and 200 mg, the generic version of Purdue Pharma's MS Contin, an opioid analgesic for moderate to severe pain management.
Rui Costa, Principal Investigator of the Champalimaud Neuroscience Programme at the Instituto Gulbenkian de Ciência, and Xin Jin, of the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, describe in the latest issue of the journal Nature, that the activity of certain neurons in the brain can signal the initiation and termination of behavioural sequences we learn anew. Furthermore, they found that this brain activity is essential for learning and executing novel action sequences, many times compromised in patients suffering from disorders such as Parkinson's or Huntington's.
Sinapis Pharma is pleased to announce that it has received notice from the FDA that its Investigational New Drug application (IND) for the use of IV methamphetamine for acute stroke was approved on April 9, 2010. "We have accomplished a great deal of work for a small company on a very tight budget. We have GMP drug ready for the Phase I clinical trial and the Phase I site is prepared to begin this protocol," said Dr. Donald Picker , the company CEO.
St. Jude Medical, Inc., a global medical device company, today announced study results on the safety and efficacy of peripheral nerve stimulation (PNS) of the occipital nerve for the management of pain and disability associated with chronic migraine, a debilitating condition that affects millions worldwide.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Erin Mcbride Cannington, MD 105 Spanish Ct, Albany, GA 31707-1282 Ph: (229) 438-7100 | Dr Erin Mcbride Cannington, MD 105 Spanish Ct, Albany, GA 31707-1282 Ph: (229) 438-7100 |
News Archive
Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia.
Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Morphine Sulfate Extended-release (ER) Tablets, 15 mg, 30 mg, 60 mg, 100 mg and 200 mg, the generic version of Purdue Pharma's MS Contin, an opioid analgesic for moderate to severe pain management.
Rui Costa, Principal Investigator of the Champalimaud Neuroscience Programme at the Instituto Gulbenkian de Ciência, and Xin Jin, of the National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, describe in the latest issue of the journal Nature, that the activity of certain neurons in the brain can signal the initiation and termination of behavioural sequences we learn anew. Furthermore, they found that this brain activity is essential for learning and executing novel action sequences, many times compromised in patients suffering from disorders such as Parkinson's or Huntington's.
Sinapis Pharma is pleased to announce that it has received notice from the FDA that its Investigational New Drug application (IND) for the use of IV methamphetamine for acute stroke was approved on April 9, 2010. "We have accomplished a great deal of work for a small company on a very tight budget. We have GMP drug ready for the Phase I clinical trial and the Phase I site is prepared to begin this protocol," said Dr. Donald Picker , the company CEO.
St. Jude Medical, Inc., a global medical device company, today announced study results on the safety and efficacy of peripheral nerve stimulation (PNS) of the occipital nerve for the management of pain and disability associated with chronic migraine, a debilitating condition that affects millions worldwide.
› Verified 2 days ago
Dennis Allen Robinson, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 105 Spanish Ct, Albany, GA 31707 Phone: 229-438-7100 Fax: 229-438-9382 | |
Michael Anthony Fowler, PAC MPAS Allergy & Immunology Medicare: Medicare Enrolled Practice Location: 105 Spanish Court, Albany, GA 31707 Phone: 229-438-7100 Fax: 229-438-9382 | |
Tracy Alan Bridges, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 105 Spanish Crt, Albany, GA 31707 Phone: 229-438-7100 Fax: 229-438-9382 | |
Dr. Jose M Theckedath, MD Allergy & Immunology Medicare: May Accept Medicare Assignments Practice Location: 1911 Palmyra Rd, Albany, GA 31701 Phone: 229-446-7227 Fax: 229-420-4365 |